## Food and Drug Administration, HHS

#### §524.1450 Moxidectin.

- (a) Specifications. Each milliliter contains 5 milligrams (mg) moxidectin (0.5 percent solution).
- (b) *Sponsor*. See No. 000010 in §510.600(c) of this chapter.
- (c) Related tolerances. See §556.426 of this chapter.
- (d)  $Special \ considerations$ . See §500.25 of this chapter.
- (e) Conditions of use-(1) Amount. Administer topically 0.5 mg per kilogram of body weight.
- (2) Indications for use. Beef and dairy cattle: For treatment and control of internal and external parasites: gastroroundworms (Ostertagia intestinal ostertagi (adult and L4, including inhibited larvae), Haemonchus placei (adult and L4), Trichostrongylus axei (adult and L4), T. colubriformis (adult and L4), Cooperia oncophora (adult and L4), C. pectinata (adult), C. punctata (adult and L4), C. spatulata (adult), C. surnabada Bunostomumand L4),phlebotomum (adult), Oesophagostomum radiatum (adult and L4), Nematodirus helvetianus (adult and L4)); lungworms (Dictyocaulus viviparus, adult and L4); cattle grubs (Hypoderma bovis, H. lineatum); mites (Chorioptes bovis, Psoroptes ovis (P. communis var. bovis)); lice (Linognathus vituli, Haematopinus Solenopotes capillatus, eurusternus. Bovicola(Damalinia) bovis); and horn flies (Haematobia irritans). To control infections and to protect from reinfection with H. placei for 14 days after treatment, O. radiatum and O. ostertagi for 28 days after treatment, and D. viviparus for 42 days after treatment.
- (3) *Limitations*. A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal.
- [63 FR 14036, Mar. 24, 1998, as amended at 65 FR 36617, June 9, 2000; 66 FR 46370, Sept. 5, 2001. Redesignated at 76 FR 48715, Aug. 9, 20111

#### § 524.1465 Mupirocin.

- (a) Specifications. Each gram of ointment contains 20 milligrams mupirocin.
- (b) Sponsors. See Nos. 000069, 025463, and 051672 in §510.600(c) of this chapter.
- (c) Conditions of use in dogs—(1) Amount. Apply twice daily. Treatment should not exceed 30 days.

- (2) Indications for use. For the topical treatment of bacterial infections of the skin, including superficial pyoderma, caused by susceptible strains of Staphylococcus aureus and S. intermedius.
- (3) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[72 FR 18119, Apr. 11, 2007, as amended at 75 FR 79296, Dec. 20, 2010]

### § 524.1484 Neomycin sulfate ophthalmic and topical dosage forms.

# § 524.1484b Neomycin sulfate, isoflupredone acetate, tetracaine hydrochloride, and myristylgamma-picolinium chloride, topical powder.

- (a) Specifications. The product contains 5 milligrams of neomycin sulfate, equivalent to 3.5 milligrams of neomycin base, 1 milligram of isoflupredone acetate, 5 milligrams of tetracaine hydrochloride and .2 milligram of myristyl-gamma-picolinium chloride in each gram of the product in a special adherent powder base.
- (b) *Sponsor*. See No. 000009 in §510.600(c) of this chapter.
- (c) Conditions of use. (1) It is used in horses, dogs, and cats in the treatment or adjunctive therapy of certain ear and skin conditions when such conditions are caused by or associated with neomycin-susceptible organisms and/or allergy. In addition the product is indicated as superficial dressing applied to minor cuts, wounds, lacerations, abrasions, and for postsurgical application where reduction of pain and inflammatory response is deemed desirable. The product may be used as a dusting powder following amputation of tails, claws, and dew-claws and following ear trimming, castrating, and such surprocedures ovariohysterectomies. The product may also be used in the treatment of acute otitis externa in dogs, acute moist dermatitis and interdigital dermatitis in dogs.
- (2) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 43 FR 18172, Apr. 28, 1978]